Astellas Pharma US, Inc. Announces Construction of New Corporate Headquarters
Japan, April 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that its US subsidiary, Astellas Pharma US, Inc.(headquarters: Deerfield, Illinois, “Astellas Pharma US” ) to construct new corporate headquarters for Americas in Glenview, Illinois.
Currently Astellas has several subsidiaries for R&D,
manufacturing, sales and marketing in the U.S. Astellas Pharma US
has already established a strong business platform in hospitals and
medical specialist areas by promoting the pharmaceutical products
such as an immunosuppressant Prograf®, a treatment for
overactive bladder VESIcare® and an injectable antifungal agent
Mycamine®. Astellas has its global development headquarters,
Astellas Pharma Global Development, Inc., in the United States to
further strengthen its drug development capabilities and
competitiveness in the global pharmaceutical market. Astellas has
decided to construct the new corporate headquarters to accommodate
the company’s growth with ample space and considering other
circumstances such as office security and leasing expiring of
current buildings.
The new corporate headquarters, which is schedule for completion in
the spring of 2012, will be two six-story buildings totaling
425,000 square feet and will cost approximately $150 million.
Posted: April 2010
